

## Effect of Celergen, a marine derivative, on *in vitro* hepatocarcinogenesis

R. Catanzaro<sup>1</sup>, N. Zerbinati<sup>2</sup>, U. Solimene<sup>3</sup>, G. Celep<sup>4</sup>, F. Marotta<sup>5,\*</sup>, A. Kushugulova<sup>6</sup>, M. Milazzo<sup>1</sup>, C. Tomella<sup>5</sup>, G. Bertuccelli<sup>5</sup>, Z. Zhumadilov<sup>6</sup>

<sup>1</sup> Department of Internal Medicine, Gastroenterology Division, University of Catania, Catania, Italy;

<sup>2</sup> CMP Medical Center & Laboratories, Pavia, Italy;

<sup>3</sup> WHO-cntr for Traditional Medicine & Biotechnology, University of Milano, Milano, Italy;

<sup>4</sup> Gazi University, Faculty of Family and Consumer Sciences Department, Nutrition and Food Technology Division, Ankara, Turkey;

<sup>5</sup> ReGenera Research Group for Aging-Intervention, Milano, Italy;

<sup>6</sup> Center for Life Sciences, Nazarbayev University, Astana, Kazakhstan.

**ABSTRACT:** The aim of this study was to test for a potential anticarcinogenic effect of Celergen, a marine derivative devoid of traceable amounts of inorganic arsenic, on cell proliferation, cell cycle progression and apoptosis in the HepG2 human liver cancer cell line. Celergen significantly inhibited the proliferation of cancer cells in a dose-dependent manner while limiting the cell cycle progression at the G1 phase and significantly inducing apoptosis. Further examination showed that Celergen enhanced expression of the *p21<sup>CIP1/WAF1</sup>*, *GADD153* genes and downregulated the *c-myc* gene. These results suggest that Celergen exerts promising chemopreventive properties to be further investigated.

**Keywords:** Antimutagenic effect, cell cycle, apoptosis, celergen, marine compound

### 1. Introduction

Marine derivatives, with their immense diversity and selection driven along millions of years of evolution may offer promising options for new drug discovery (1-5). In particular, several marine bioactive compounds are under study for their potential antitumor effect (6-9). Although the detailed mechanisms involved are still a matter of study, antioxidative and antimutagenic properties have been advocated for (10-12). We have recently shown that Celergen, a popular GMP-controlled marine bioceutical, could significantly inhibit ultraviolet (UV)-induced matrix-metalloproteinases (MMP) transcription and exert an antioxidant effect protecting skin fibroblasts (13). On the other hand, most recently the same food

supplement has been vaguely suggested to be implicated in a case report in which the user showed increased levels of  $\alpha$ -fetoprotein (14). Although this report suffers some limitations and a possible major methodological flaw, the issue deserved further clarification, given that several herbal supplements, once believed as safe or even claimed to be "liver protectors" have been recently shown to be potentially hepatotoxic or even mutagenic (15-18). Thus, the aim of the present study was to test the novel biomarine derivative Celergen on *in vitro* liver carcinogenesis.

### 2. Materials and Methods

#### 2.1. Chemicals

Celergen was obtained from Swisscap company (100 mg composition: DNA extract from fish milt 46 mg, fish collagen hydrolysate plus fish elastin 35 mg, whole fish protein hydrolysate 6 mg, lutein-coenzyme Q10-selenium 11 mg). As a pre-requisite, samples were blindly sent to an official Good Manufacturing Practice and Good Laboratory Practice registered toxicology laboratory which found no traceable amounts of heavy metals including organic and inorganic arsenic, having set a threshold of > 5 ppm (Redox Lab, Monza, Italy, report n. 2013001054/LAB). 7,12-Dimethylbenz[a]anthracene (DMBA) and 12-Q-tetradecanoylphorbol-13-acetate (TPA) were obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA). 4-Nitroquinoline I-oxide (4NQO) was obtained from Nacalai Tesque Co. (Kyoto, Japan).

#### 2.2. *In vitro* analysis of cell growth

Human liver cancer cell line HepG2 were cultured in DMEM supplemented with 10% fetal bovine serum and incubated at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> in air. HepG2 cells were then seeded at a density of  $4 \times 10^4$  cells/2 mL medium in 35-mm diameter

\*Address correspondence to:

Dr. F. Marotta, Piazza Firenze, 12, 20154 Milano, Italy.  
E-mail: fmarchimede@libero.it

dishes. Celergen were dissolved in tetrahydrofuran (THF) including 0.025% butylhydroxytoluene (BHT, as an antioxidant) and diluted to its final concentration expressed as  $\mu\text{g}/\text{mL}$  in each culture dish. An equivalent volume of vehicle (THF + BHT) was added to control dishes and it showed no measurable effect on HepG2 cells. Celergen was added at graded concentrations 1 day following the inoculation. At the 72 h observation, the number of viable cells was counted using a trypan blue dye exclusion methodology.

### 2.3. Flow cytometry

Cells were plated at a density of  $1 \times 10^6$  cells/10 mL medium in 100 mm diameter dishes. Celergen was added 1 day after the inoculation. Cells were harvested from culture dishes by trypsinization and centrifugation. After a wash with phosphate buffered solution (PBS) (-), cells were suspended in a 0.1% Triton X-100 solution. After the suspension was filtered through 50  $\mu\text{m}$  nylon mesh, 0.1% RNase A and 50  $\mu\text{g}/\text{mL}$  propidium iodide were added to stain DNA. The DNA content in stained nuclei was analyzed by a flow cytometer (FACS Calibur™, Becton-Dickinson, Franklin Lakes, NJ, USA). The percentage distribution of cells in each cell cycle phase was determined using ModFit LT™ software (Becton-Dickinson) based on DNA histograms. Five separate experiments were used each time to determine the final values.

### 2.4. Isolation of total RNA

HepG2 cells were plated at a density of  $1 \times 10^6$  cells/10 mL medium in 100 mm diameter dishes. Celergen was added 24 h after the inoculation. Total RNA was isolated from the cells at pre-fixed times in the absence or presence of Celergen using RNeasyR Kit (QIAGEN GmbH, Hilden, Germany). Briefly, total RNA was adsorbed onto a silica membrane following cell lysis. Membranes were subsequently washed and RNA was eluted with 50/11 of RNase-free water. Final RNA concentrations were assessed by spectrophotometry.

### 2.5. Real-time quantitative RT-PCR

Total RNA was isolated from HepG2 cells as described above. Total RNA (5  $\mu\text{g}$ ) was transcribed to cDNA in a 20  $\mu\text{L}$  reaction volume, with Superscript II Reverse transcriptase (Invitrogen Corp., Carlsbad, CA, USA), using oligo (dT) 12-18 primers. The reaction mixture was incubated at 42°C for 50 min, then at 70°C for 15 min. An equivalent volume of cDNA solution was used for the quantification of specific cDNA by real-time quantitative RT-PCR. The primer sequences used were as follows: for the *p21<sup>CIP1/WAF1</sup>* gene (318 bp), 5'-ATTAGCAGCGGAACAAGGAGTCAGACAT3' and 5'-CTGTGAAAGACACAGAACAGT

ACAGGGT-3', for *GADD153* (309 bp), 5'GAAACGGAAACAGAGTGGTCATTCCCC-3' and 5'-GTGGGATTGAGGGTCACATCATTGGCA-3', for *c-myc* (209 bp), 5'-GGCAAAGGTCAGAGTCTGG-3' and 5'-GTGCATTTTCGGTTGTTGC-3', for *glyceraldehyde 3-phosphate dehydrogenase (GAPDH)*, 181 bp), 5'-CAACTACATGGTTTACATGTTC-3' and 5'-GCCAGTGGACTCCACGAC-3'. Real-time quantitative RT-PCR was performed with the LightCycler™ system (Roche Diagnostics GmbH, Mannheim, Germany) using a SYBR Green I Kit as instructed by the manufacturer. *GAPDH*, *p21<sup>CIP1/WAF1</sup>* and *GADD153* were amplified with a pre-cycling hold at 95°C for 10min, followed by 30 cycles of denaturation at 95°C for 15 s, annealing at 58°C for 5 s, and extension at 72°C for 10 s. *c-myc* was amplified with a pre-cycling hold at 95°C for 10 min, followed by 30 cycles of denaturation at 95°C for 15 s, annealing at 63°C for 5 s and extension at 72°C for 10 s. To confirm amplification specificity, the PCR products were subjected to a melting curve analysis. Quantification data were analyzed using LightCycler analysis software. The expression levels of *p21<sup>CIP1/WAF1</sup>*, *GADD153*, and *c-myc* were normalized to the level of GAPDH mRNA of the same sample.

### 2.6. Statistical analysis

For statistical analysis "One Way" variance analysis was employed and significance between the experimental and control groups was determined by Bonferroni's method. A difference of  $p < 0.05$  was considered significant. Results were expressed as mean  $\pm$  S.D.


## 3. Results

### 3.1. HepG2 cell proliferation: in vitro effects of Celergen


Treatment of HepG2 cells with Celergen brought about a significant inhibition of human liver cancer cell proliferation in a dose-dependent manner. Three days after the incubation with 25  $\mu\text{M}$ , 50  $\mu\text{M}$ , 100  $\mu\text{M}$  and 200  $\mu\text{M}$  Celergen, HepG2 cell growth decreased to 63, 52, 38 and 27% of the control, respectively. The concentration of Celergen with 50% growth inhibition was calculated as 50  $\mu\text{M}$  (Figure 1).

### 3.2. Effect of Celergen on G1 arrest and apoptosis in HepG2 cells

The DNA content of HepG2 cells was calculated by flow cytometry analysis to identify whether the growth inhibitory effect of Celergen was determined by specific actions on cell cycle-related events. From DNA histograms it appeared that Celergen enabled a not significant trend increase of the ratio of G1 cells, but most significantly it increased pre-G1 apoptotic cells at



**Figure 1. Growth inhibitory effect of Celergen on HepG2 cells.** Cells were cultured for 72 h with or without Celergen at concentrations ranging from 25 to 200  $\mu$ M. On day 3, the number of viable cells was determined. Data are expressed as means  $\pm$  S.D. of three separate experiments.



**Figure 2. Effect of Celergen on cell cycle and apoptosis in HepG2 cells.** HepG2 cells were treated with Celergen at ID 50 or ID 75 for 72 h and stained with propidium iodide to assess DNA content. The percentage of cells in each phase of the cell cycle was assessed by flow cytometric analysis. Data are expressed as means  $\pm$  S.D. of five separate experiments. Left vertical line indicates the ratio of each phase in viable cells. Right vertical line indicates the percentage of apoptotic cells. White bars: G1; dotted bars: S; black bars: G2/M and grey bars: apoptosis. \*  $p < 0.01$  compared with control.


the 72h observation ( $p < 0.005$ , Figure 2). On the other hand, the effect of Celergen on the cell cycle on days 1 and 2 was not significant (not shown)..

### 3.3. Gene expression of $p21^{CIP1/WAF1}$ , $GADD153$ and $c-myc$ expression: effect of Celergen regulation

The effects of Celergen on the expression of cell cycle and apoptosis-related genes were examined using real-time quantitative RT-PCR. Significant induction of  $p21^{CIP1/WAF1}$  and  $GADD153$  was clearly observed at 48 h following treatment with Celergen and it was maintained throughout the observation period (72 h) while a significant late downregulation of  $c-myc$  occurred as well ( $p < 0.01$ , Figure 3).

## 4. Discussion

Celergen is a popular marine derivative containing DNA, collagen elastin and protein extracts and we



**Figure 3. Effect of Celergen on  $p21^{CIP1/WAF1}$ ,  $GADD153$ , and  $c-myc$  mRNA expression.** Real-time quantitative RT-PCR was performed with 5  $\mu$ g of total RNA from HepG2 cells treated with 50  $\mu$ M Celergen or vehicle alone (control) for the test periods indicated. Values are means  $\pm$  S.D. of five separate tests. All values were normalized to the GAPDH expression level. \*  $p < 0.05$  compared with control.

have been recently shown that it exhibits a strong skin fibroblast protecting effect against UV irradiation (13).

In the present study, Celergen was shown to significantly inhibit cell growth *via* induction of G1 arrest of the cell cycle and apoptosis in HepG2 cells. To explore the action mechanism of cell cycle inhibition by Celergen, we assessed the expression of cell cycle and apoptosis related genes and found that the expression of  $p21^{CIP1/WAF1}$  and  $GADD153$  was significantly induced by Celergen. It is known that  $p21^{CIP1/WAF1}$  is significantly induced by DNA damage and regulates the G1 and G2/M checkpoints (19,20) and that the induction of  $p21^{CIP1/WAF1}$  usually follows a

p53 dependent mechanism (21). Moreover, *GADD153* and *c-myc* are known to be involved in apoptosis progression. *GADD153* is a member of the CCAAT/enhancer-binding protein family of transcription factors and its expression is markedly enhanced by various cellular stresses (22,23). On the other hand, *c-myc* is a proto-oncogene and is implicated in various processes including cell growth, proliferation and cell death (24). In particular, the overexpression of *c-myc* represents a genetic abnormality frequently found in hepatocellular carcinoma (HCC) (25). Indeed, the relevance of *c-myc* expression in HCC has been confirmed in transgenic mice studies (26) and in clinics where overexpression of this gene is detected in most HCC patients while correlating also with poor prognosis (27). In our study, the induction of p21<sup>CIP1/WAF1</sup> and *GADD153* occurred significantly at 48 h after treatment with Celergen and subsequently, an increase in G1 phase and apoptotic pre-G1 cells was observed at 72 h. However, *c-myc* showed a late but significant downregulation. Since p53 is known to be functional in HepG2 cells, p21<sup>CIP1/WAF1</sup> is likely to have been induced by a mechanism which depends on p53 and may be implicated in G1 arrest exerted by Celergen. Nonetheless, the induction of apoptosis by Celergen may be caused by *GADD153* and has to be considered as well.

In summary, our data suggest that Celergen inhibits the proliferation of HepG2 cells and induces G1 arrest and apoptosis. The induction was associated with enhanced expression of p21<sup>CIP1/WAF1</sup>, *GADD153* but suppression of *c-myc*. These results suggest that such marine compounds may have anticarcinogenic properties while more finely-detailed proteomic studies are awaited. This data is in contrast with the albeit isolated clinical report of Chua *et al.* (14) suggesting an arsenic-related hepatocarcinogenesis effect of the same compound. However, that study bears the main methodological bias in that the authors measured the whole arsenic content, while the literature has clearly demonstrated that only the inorganic component is the one with the noxious effect (28) and the only one deserving monitoring from major epidemiological studies (29,30). On the contrary, the organic one is regarded as safe (31) and its concentration may also vary (32) as probably occurred in their study. For instance, seafood and seaweeds generally contain almost completely nontoxic organic arsenic such as arsenosugars (33). Thus, their suggestion cannot be supported and their observed abnormality of  $\alpha$ -fetoprotein observed in their case report has to be correlated to other factors (episodic aflatoxin exposure, either environmental or food-borne *etc.*) which have not been analyzed in their report together with the lack of a separate measurement of organic and inorganic arsenic content. From the above, the study of Chua *et al.* has to be disregarded similarly because of what happened

with a similar case of a different seafood compound after review by a number of experts in the field (34-36). While our study needs further research and *in vivo* follow up, our general conclusion is that marine derivatives, if properly farmed, collected and processed maintain a promising potential as a safe source of beneficial treatment.

## References

1. Lorenzetti A, Marotta F, Yadav H, Celep G, Minelli E, Carrera-Bastos P, Jain S, Polimeni A, Solimene U. Improving sperm quality and spermatogenesis through a bioactive marine compound: An experimental study. *Acta Biomed.* 2012; 83:108-113.
2. Catanzaro R, Marotta F, Jain S, Rastmanesh R, Allegrì F, Celep G, Lorenzetti A, Polimeni A, Yadav H. Beneficial effect of a sturgeon-based bioactive compound on gene expression of tumor necrosis factor-alpha, matrix metalloproteinases and type-10 collagen in human chondrocytes. *J Biol Regul Homeost Agents.* 2012; 26:337-345.
3. Newman DJ, Cragg GM. Marine natural products and related compounds in clinical and advanced preclinical trials. *J Nat Prod.* 2004; 67:1216-1238.
4. Cabrita MT, Vale C, Rauter AP. Halogenated compounds from marine algae. *Mar Drugs.* 2010; 8:2301-2317.
5. Newman DJ, Cragg GM. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. *Curr Med Chem.* 2004; 11:1693-1713.
6. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH. Marine natural products as anticancer drugs. *Mol Cancer Ther.* 2005; 4:333-342.
7. Singh R, Sharma M, Joshi P, Rawat DS. Clinical status of anti-cancer agents derived from marine sources. *Anticancer Agents Med Chem.* 2008; 8:603-617.
8. Provencio M, Sánchez A, Gasent J, Gómez P, Rosell R. Cancer treatments: Can we find treasures at the bottom of the sea? *Clin Lung Cancer.* 2009; 10:295-300.
9. Jimeno J, López-Martín JA, Ruiz-Casado A, Izquierdo MA, Scheuer PJ, Rinehart K. Progress in the clinical development of new marine-derived anticancer compounds. *Anticancer Drugs.* 2004; 15:321-329.
10. Tang HG, Wu TX, Zhao ZY, Pan XD. Effects of fish protein hydrolysate on growth performance and humoral immune response in large yellow croaker (*Pseudosciaena crocea* R.). *J Zhejiang Univ Sci B.* 2008; 9:684-690.
11. Theodore AE, Raghavan S, Kristinsson HG. Antioxidative activity of protein hydrolysates prepared from alkaline-aided channel catfish protein isolates. *J Agric Food Chem.* 2008; 56:7459-7466.
12. Yang Y, Zhang Z, Pe, X, Han H, Wang J, Wang L, Long Z, Shen X, Li Y. Immunomodulatory effects of marine oligopeptide preparation from Chum Salmon (*Oncorhynchus keta*) in mice. *Food Chem.* 2009; 113:464-470.
13. Marotta F, Kumari A, Yadav H, Polimeni A, Soresi V, Lorenzetti A, Naito Y, Jain S. Biomarine extracts significantly protect from ultraviolet A-induced skin photoaging: An ex vivo study. *Rejuvenation Res.* 2012; 15:157-160.
14. Chua C, Tan IB, Choo SP, Toh HC. Increased

- $\alpha$ -fetoprotein likely induced by complementary health products. *J Clin Oncol.* 2013; 31:e80-82.
15. Navarro VJ, Bonkovsky HL, Hwang SI, Vega M, Barnhart H, Serrano J. Catechins in dietary supplements and hepatotoxicity. *Dig Dis Sci.* 2013; 58:2682-2690.
  16. Teschke R, Schwarzenboeck A, Eickhoff A, Frenzel C, Wolff A, Schulze J. Clinical and causality assessment in herbal hepatotoxicity. *Expert Opin Drug Saf.* 2013; 12:339-366.
  17. Brandon-Warner E, Eheim AL, Foureau DM, Walling TL, Schrum LW, McKillop IH. Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice. *Cancer Lett.* 2012; 326:88-95.
  18. McCormick DL, Hollister JL, Bagg BJ, Long RE. Enhancement of murine hepatocarcinogenesis by all-trans-retinoic acid and two synthetic retinamides. *Carcinogenesis.* 1990; 11:1605-1609.
  19. Dang CV. *c-Myc* target genes involved in cell growth, apoptosis, and metabolism. *Mol Cell Biol.* 1999; 19:1-11.
  20. Kurland JF, Tansey WP. Myc-mediated transcriptional repression by recruitment of histone deacetylase. *Cancer Res.* 2008; 68:3624-3629.
  21. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The *c-Myc* target gene network. *Semin Cancer Biol.* 2006; 16:253-264.
  22. Liao Y, Fung TS, Huang M, Fang SG, Zhong Y, Liu DX. Up-regulation of CHOP/GADD153 during coronavirus infectious bronchitis virus infection modulates apoptosis by restricting activation of the extracellular signal-regulated kinase pathway. *J Virol.* 2013; 87:8124-8134.
  23. De Luca P, Moiola CP, Zalazar F, Gardner K, Vazquez ES, De Siervi A. BRCA1 and p53 regulate critical prostate cancer pathways. *Prostate Cancer Prostatic Dis.* 2013; 16:233-238.
  24. Zhao Y, Jian W, Gao W, Zheng YX, Wang YK, Zhou ZQ, Zhang H, Wang CJ. RNAi silencing of *c-Myc* inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: *c-Myc* silencing in hepatocellular carcinoma cell. *Cancer Cell Int.* 2013; 13:23-28.
  25. Lin CP, Liu CR, Lee CN, Chan TS, Liu HE. Targeting *c-Myc* as a novel approach for hepatocellular carcinoma. *World J Hepatol.* 2010; 2:16-20
  26. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyanenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. *Cancer Res.* 2011; 71:2286-2297.
  27. Peng S, Lai P, Hsu H. Amplification of the *c-myc* gene in human hepatocellular carcinoma: biologic significance. *J Formos Med Assoc.* 1993; 92:866.
  28. Huang CY, Su CT, Chung CJ, Pu YS, Chu JS, Yang HY, Wu CC, Hsueh YM. Urinary total arsenic and 8-hydroxydeoxyguanosine are associated with renal cell carcinoma in an area without obvious arsenic exposure. *Toxicol Appl Pharmacol.* 2012; 262:349-354.
  29. Calderon RL, Hudgens EE, Carty C, He B, Le XC, Rogers J, Thomas DJ. Biological and behavioral factors modify biomarkers of arsenic exposure in a U.S. population. *Environ Res.* 2013; 126:134-144.
  30. Osorio-Yáñez C, Ayllon-Vergara JC, Aguilar-Madrid G, Arreola-Mendoza L, Hernández-Castellanos E, Barrera-Hernández A, De Vizcaya-Ruiz A, Del Razo LM. Carotid intima-media thickness and plasma asymmetric dimethylarginine in mexican children exposed to inorganic arsenic. *Environ Health Perspect.* 2013; 121:1090-1096.
  31. Francesconi KA, Edmonds JS. Arsenic and marine organisms. In: *Advances in Inorganic Chemistry*, Vol. 44. 1997; 44:147.
  32. Taylor VF, Jackson BP, Siegfried M, Navratilova J, Francesconi KA, Kirshtein J, Voytek M. Arsenic speciation in food chains from mid-Atlantic hydrothermal vents. *Environ Chem.* 2012; 9:130-138.
  33. Kaise TOY, Ochi T, Okubo T, Hanaoka K, Irgolic KJ, Sakurai T, Matsubara C. Toxicological study of organic arsenic compound in marine algae using mammalian cell culture technique. *J Food Hyg Soc Jpn.* 1996; 37:135-141.
  34. Fabricant D. Arsenic in herbal kelp supplements: concentration, regulations, and labeling. *Environ Health Perspect.* 2007; 115:A574.
  35. Lewis AS. Organic versus inorganic arsenic in herbal kelp supplements. *Environ Health Perspect.* 2007; 115:A575.
  36. McGuffin M, Dentali S. Safe use of herbal kelp supplements. *Environ Health Perspect.* 2007; 115:A575-576.

(Received September 6, 2013; Revised October 10, 2013, Re-revised October 26, 2013; Accepted October 28, 2013)